Autonomix Medical (NASDAQ:AMIX) & Atossa Genetics (NASDAQ:ATOS) Financial Comparison

Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Atossa Genetics and Autonomix Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	2	1	2.40
Autonomix Medical	1	1	1	0	2.00

Atossa Genetics presently has a consensus target price of $6.33, indicating a potential upside of 973.45%. Autonomix Medical has a consensus target price of $5.00, indicating a potential upside of 809.09%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Autonomix Medical.

Valuation & Earnings

This table compares Atossa Genetics and Autonomix Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($0.24)	-2.46
Autonomix Medical	N/A	N/A	-$11.41 million	($4.65)	-0.12

Atossa Genetics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Atossa Genetics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -2.87, indicating that its stock price is 387% less volatile than the S&P 500.

Institutional and Insider Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 9.5% of Atossa Genetics shares are owned by company insiders. Comparatively, 6.2% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Atossa Genetics and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-49.42%	-44.76%
Autonomix Medical	N/A	-213.42%	-172.57%

Summary

Atossa Genetics beats Autonomix Medical on 10 of the 12 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.